← Back to Clinical Trials
Recruiting NCT02382601

NCT02382601 Longitudinal Study of Intra-Uterine Growth Restriction

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02382601
Status Recruiting
Phase
Sponsor University of Colorado, Denver
Condition IUGR
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2015-04
Primary Completion 2028-12

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 45 Years
Study Type OBSERVATIONAL
All Conditions
Interventions
UltrasoundMRIBlood collection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2015-04 with a primary completion date of 2028-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigation will employ a longitudinal approach in which every fetus diagnosed to be SGA (Small for Gestational Age ) will be studied at frequent intervals with sophisticated imaging techniques to assess subtle physiologic changes in the brain, heart, and placenta over time. These findings will be correlated with neurological and cardiovascular function in the newborn and early childhood. This research initiative should yield diagnostic and therapeutic templates that will improve the quality of life of IUGR babies in addition to providing important information that will better inform current diagnostic practices.

Eligibility Criteria

Inclusion Criteria: * Patients with diagnosed SGA by an ultrasound estimated fetal weight (EFW) of less than the 10th percentile or a fetal abdominal circumference of less than the 5th percentile will be included in the study at the time of their first examination. Exclusion Criteria: * Patients \< 18 years of age, and chromosomal anomalies as identified by regular aneuploidy screening.

Contact & Investigator

Central Contact
Principal Investigator

John Hobbins, MD

PRINCIPAL INVESTIGATOR

University of Colorado, Denver

Frequently Asked Questions

Who can join the NCT02382601 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying IUGR. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02382601 currently recruiting?

Yes, NCT02382601 is actively recruiting participants. Contact the research team at emma.peek@cuanschutz.edu for enrollment information.

Where is the NCT02382601 trial being conducted?

This trial is being conducted at Aurora, United States.

Who is sponsoring the NCT02382601 clinical trial?

NCT02382601 is sponsored by University of Colorado, Denver. The principal investigator is John Hobbins, MD at University of Colorado, Denver. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology